Yang JC - Search Results

1

B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells.

Kochenderfer JN, Dudley ME, Feldman SA, Wilson WH, Spaner DE, Maric I, Stetler-Stevenson M, Phan GQ, Hughes MS, Sherry RM, Yang JC, Kammula US, Devillier L, Carpenter R, Nathan DA, Morgan RA, Laurencot C, Rosenberg SA. Kochenderfer JN, et al. Among authors: yang jc. Blood. 2012 Mar 22;119(12):2709-20. doi: 10.1182/blood-2011-10-384388. Epub 2011 Dec 8. Blood. 2012. PMID: 22160384 Free PMC article. Clinical Trial.

2

Clinical application of IL6 in cancer therapy.

Mulé JJ, Marcus SG, Yang JC, Weber JS, Rosenberg SA. Mulé JJ, et al. Among authors: yang jc. Res Immunol. 1992 Sep;143(7):777-9. doi: 10.1016/0923-2494(92)80023-e. Res Immunol. 1992. PMID: 1439156 Clinical Trial. No abstract available.

3

A pilot study of the combination of interleukin-2-based immunotherapy and radiation therapy.

Lange JR, Raubitschek AA, Pockaj BA, Spencer WF, Lotze MT, Topalian SL, Yang JC, Rosenberg SA. Lange JR, et al. Among authors: yang jc. J Immunother (1991). 1992 Nov;12(4):265-71. doi: 10.1097/00002371-199211000-00007. J Immunother (1991). 1992. PMID: 1477077 Clinical Trial.

4

Surgical resection of metastatic renal cell carcinoma and melanoma after response to interleukin-2-based immunotherapy.

Sherry RM, Pass HI, Rosenberg SA, Yang JC. Sherry RM, et al. Among authors: yang jc. Cancer. 1992 Apr 1;69(7):1850-5. doi: 10.1002/1097-0142(19920401)69:7<1850::aid-cncr2820690729>3.0.co;2-i. Cancer. 1992. PMID: 1551067 Clinical Trial.

5

The use of interleukin-2 and lymphokine-activated killer cells for the treatment of patients with non-Hodgkin's lymphoma.

Weber JS, Yang JC, Topalian SL, Schwartzentruber DJ, White DE, Rosenberg SA. Weber JS, et al. Among authors: yang jc. J Clin Oncol. 1992 Jan;10(1):33-40. doi: 10.1200/JCO.1992.10.1.33. J Clin Oncol. 1992. PMID: 1727923

6

Relapse after response to interleukin-2-based immunotherapy: patterns of progression and response to retreatment.

Sherry RM, Rosenberg SA, Yang JC. Sherry RM, et al. Among authors: yang jc. J Immunother (1991). 1991 Oct;10(5):371-5. doi: 10.1097/00002371-199110000-00009. J Immunother (1991). 1991. PMID: 1790145

7

Murine studies using polyethylene glycol-modified recombinant human interleukin 2 (PEG-IL-2): antitumor effects of PEG-IL2 alone and in combination with adoptive cellular transfer.

Yang JC, Schwarz SL, Perry-Lalley DM, Rosenberg SA. Yang JC, et al. Lymphokine Cytokine Res. 1991 Dec;10(6):475-80. Lymphokine Cytokine Res. 1991. PMID: 1804310

8

Acute and long-term effects on limb function of combined modality limb sparing therapy for extremity soft tissue sarcoma.

Stinson SF, DeLaney TF, Greenberg J, Yang JC, Lampert MH, Hicks JE, Venzon D, White DE, Rosenberg SA, Glatstein EJ. Stinson SF, et al. Among authors: yang jc. Int J Radiat Oncol Biol Phys. 1991 Nov;21(6):1493-9. doi: 10.1016/0360-3016(91)90324-w. Int J Radiat Oncol Biol Phys. 1991. PMID: 1938558

9

An improved method for growing murine tumor-infiltrating lymphocytes with in vivo antitumor activity.

Yang JC, Perry-Lalley D, Rosenberg SA. Yang JC, et al. J Biol Response Mod. 1990 Apr;9(2):149-59. J Biol Response Mod. 1990. PMID: 1971302

10

Lysis of autologous melanoma cells by tumor-infiltrating lymphocytes: association with clinical response.

Aebersold P, Hyatt C, Johnson S, Hines K, Korcak L, Sanders M, Lotze M, Topalian S, Yang J, Rosenberg SA. Aebersold P, et al. J Natl Cancer Inst. 1991 Jul 3;83(13):932-7. doi: 10.1093/jnci/83.13.932. J Natl Cancer Inst. 1991. PMID: 2067036 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

1,797 results

Search Page

Filters